Skip to main content
Dean Brenner, MD, Oncology, Ann Arbor, MI

DeanElliotBrennerMD

Oncology Ann Arbor, MI

Professor, Medical Oncology, University of Michigan Health System

Are you Dr. Brenner?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

  • Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
    You already have 26 invites waiting!
  • Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

  • Office

    1500 East Medical Center Dr
    B1 Floor Cancer Recp D
    Ann Arbor, MI 48109
    Phone+1 734-647-8903

Summary

  • Dr. Dean Brenner, MD is an oncologist in Ann Arbor, Michigan. He is currently licensed to practice medicine in Michigan, Tennessee, and Pennsylvania. He is affiliated with University of Michigan Medical Center and Veterans Affairs Ann Arbor Healthcare System.

Education & Training

  • National Institutes of Health Clinical Center
    National Institutes of Health Clinical CenterFellowship, Medical Oncology, 1978 - 1980
  • Penn State Milton S Hershey Medical Center
    Penn State Milton S Hershey Medical CenterResidency, Internal Medicine, 1974 - 1977
  • Drexel University College of Medicine
    Drexel University College of MedicineClass of 1974

Certifications & Licensure

  • MI State Medical License
    MI State Medical License 1989 - 2026
  • PA State Medical License
    PA State Medical License 1975 - 1990
  • TN State Medical License
    TN State Medical License 1981 - 1986
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Grant Support

  • Translating Cancer Prevention Research In The Developing WorldNational Cancer Institute2011
  • Translational Research In GI CancerNational Cancer Institute2010–2011
  • P1 - Omega-3 Fatty Acids And Colorectal Cancer PreventionNational Cancer Institute2010–2011
  • Great Lakes/New England Clinical Validation CenterNational Cancer Institute2010–2011
  • Administrative CoreNational Cancer Institute2010–2011
  • Great Lakes/New England Clinical Epidemiology/ValidationNational Cancer Institute2005–2010
  • Clin Study Of Safety, Pharmacokinetics And Pharmacodynamics Of ResveratrolNational Center For Research Resources2007
  • Translational Research In Cancer PreventionNational Cancer Institute2007
  • University Of Michigan Comprehensive Cancer Center Ccop*National Cancer Institute2005–2007
  • Pharmacokinetic Trial Of Curcuminoids Administered In A Capsule FormulationNational Center For Research Resources2004
  • University Of Michigan Comprehensive Cancer CenterNational Cancer Institute2004
  • Cancer Prevention: Translation Of Molecular RevolutionNational Cancer Institute2004
  • Great Lakes New England Clinical And Epidemiology CenterNational Cancer Institute2000–2004
  • University Of Michigan CCOP Research BaseNational Cancer Institute1997–2003
  • Pilot--Biomedical ProgramNational Cancer Institute2001–2002
  • Umcc 9715--Pharmacokinetics Of Curcumin Administered As Micronized FormulationNational Center For Research Resources1999–2000
  • Chemoprevention Of Defluoromethylornithine In Intestinal Barretts EsophagusNational Center For Research Resources1999–2000
  • Phase I Single &Multiple-Dose SafetyDivision Of Cancer Prevention And Control1997–2000
  • Aspirin Modulation Of Premalignant Biomarkers Of Colorectal EpitheliumNational Center For Research Resources1997–1999
  • Phase II Clinical Trials Of New Chemopreventive AgentsDivision Of Cancer Prevention And Control1997–1999
  • Aspirin Concentrations In Rectal EpitheliumNational Center For Research Resources1996–1999
  • Translational Chemoprevention--Breast And Colon CancerNational Cancer Institute1997
  • Aspirin Modulation Of Biomarkers Of Colorectal EpitheliumNational Center For Research Resources1996
  • Antineoplastic Drug Hepatic InteractionsNational Cancer Institute1989–1990
  • Antineoplastic Drug Hepatic InteractionsNational Cancer Institute1988

Professional Memberships